Darrick Carter, Ph.D.

Experience

 

2002-present Corixa Corporation Seattle, WA

Group Leader

  • Led an Analytical Biochemistry group in Process Development.
 

2000- present Proteinchemist.comä Seattle, WA

Webmaster

  • Started proteinchemist.comä an E-business web site aimed sharing protein biochemical reactions, analytical and chromatographic methods.
  • Designed and maintained the web site.
  • Built dynamic content including 3D engines to display atomic coordinates, automated kinetic analysis, and a variety of primary sequence analysis programs using JAVA and PERL integrated in a DHTML setting.
 

2001-2002 Corixa Corporation Seattle, WA

Project Leader

  • Designated Project Leader to develop and lead a candidate TB vaccine through development to Phase I
 

2000-2001 Corixa Corporation Seattle, WA

Research Scientist II

  • Used mass spectrometry to identify up-regulated proteins in transformed cells
  • Lung and colon tumor proteomics combining biochemical techniques with LC – tandem MS to discover differentially expressed proteins
  • Proteomics using P. acnes and N-terminal sequencing by Edman degradation to quickly identify and patent expressed genes
  • Developed a manufacturing process and process controls for GMP manufacture of a recombinant vaccine protein now in Phase 1 clinical trials
  • Assisted in Chemistry and Manufacturing Controls section of Investigational New Drug application and the development of Standard Operating Procedures for in-process and product release tests

 

 
 

1998-2000 Corixa Corporation Seattle, WA

Associate Research Scientist

  • Directed the purification of over 120 recombinant vaccine target proteins
  • Assisted in the proteomics identification of a novel Tb diagnostic marker
  • Purified native proteins from cancer cell lines
  • Identified a novel breast cancer marker
  • Molecular modeling of MHC molecules
  • GLP and pre-GMP process development for vaccine development
 

1997-1998 Oregon Health Sciences U. Portland, OR

Postdoctoral Fellow

  • Crystallized and characterized targeted mutants in recombinantly expressed parasite proteins
  • Purified new parasite drug target in the purine salvage pathway of T. gondii
  • Crystallized the novel drug target
 

1993-1997 Oregon Health Sciences U. Portland, OR

Graduate Student

  • Produced and purified multiple parasite proteins using recombinant and native sources.
  • Developed novel inhibitor leads for drug targets in the purine salvage pathway.
  • Kinetic and mechanistic characterization of parasite drug target enzymes
  • Assisted in determining the X-ray crystal structure of a parasite drug target
  • Taught classes in biochemistry for the "Biology of Parasitism" course in Woods Hole.
 

1990-1993 Oregon Health Sciences U. Portland, OR

Undergraduate Research Assistant

  • Developed purifications for active enzymes and nutrient peptides
  • Age dependent protein modification research using directed chemical modification of proteins and peptide polymerization

 

Honors

 

  • 1990 Award for Organic Chemistry of the German Chemical Society
  • 1990/1991 DeLoach Scholarship for Biochemistry
  • 1991/1992 Milton-Harris Scholarship for Biochemistry
  • 1992/1993 Milton-Harris Scholarship for Biochemistry
  • 1993 Summa cum laude B.S. in Biochemistry and Biophysics
  • 1993 Phi Kappa Phi Membership
  • 1994 Tartar Fellowship of the Medical Research Foundation
  • 1995 Award for Graphics / Graduate Research Forum
  • 1996 Award for Best Overall Presentation / Graduate Research Forum
  • 1996 Dr. Kenneth Warren Memorial Award / Woods Hole, MA
  • 1996 Congenital Heart Research Center Student Travel Award
  • 1997 NRSA Postdoctoral Fellowship

Publications

 

  • Carter DA, et al. "Determination of beta-isomerized aspartic acid as the corresponding alcohol." Journal of Protein Chemistry 1994 January; 13(1): pp. 97-106.
  • Carter DA, et al. "Trapping succinimides in aged polypeptides by chemical reduction. " Journal of Protein Chemistry 1994 January ;13(1): pp. 89-96.

  • Ullman B, Carter D. "Hypoxanthine-guanine phosphoribosyltransferase as a therapeutic target in protozoal infections." Infectious Agents Disease 1995 March; 4(1): pp. 29-40. Review.
  • Jiang Y, Allen TE, Carter D, Ray DS, Ullman B. "Crithidia fasciculata: isolation, sequencing, and expression of the hypoxanthine-guanine phosphoribosyltransferase gene" Experimental Parasitology 1996 January; 82(1): pp. 73-75.
  • Donald RGK, Carter D, Ullman B, Roos DS. "Insertional tagging, cloning, and expression of the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyltransferase gene. Use as a selectable marker for stable transformation. " Journal of Biological Chemistry 1996 June 14; 271(24): pp. 14010-14019.
  • Schumacher MA, Carter D, Ross DS, Ullman B, Brennan RG. "Crystal structures of Toxoplasma gondii HGXPRTase reveal the catalytic role of a long flexible loop." Nature Structural Biology 1996 October; 3(10): pp 881-887.

 

 

  • Ullman B, Carter D "Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates. " International Journal of Parasitology 1997 February; 27(2): pp. 203-213.
  • Carter D, Donald RG, Roos D, Ullman B. "Expression, purification, and characterization of uracil phosphoribosyltransferase from Toxoplasma gondii. " Molecular and Biochemical Parasitology 1997 August; 87(2): pp. 137-144.
  • Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK. "Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance." Journal of Infectious Disease. 1997 December; 176(6): pp. 1590-1596.
  • Shih S, Hwang HY, Carter D, Stenberg P, Ullman B. "Localization and targeting of the Leishmania donovani hypoxanthine-guanine phosphoribosyltransferase to the glycosome. " Journal of Biological Chemistry 1998 January 16; 273(3): pp. 1534-1541.
  • Schumacher MA, Carter D, Scott DM, Roos DS, Ullman B, Brennan RG. "Crystal structures of Toxoplasma gondii uracil phosphoribosyltransferase reveal the atomic basis of pyrimidine discrimination and prodrug binding." EMBO Journal 1998 June 15; 17(12): pp. 3219-32.
  • Darling JA, Sullivan WJ Jr, Carter D, Ullman B, Roos DS "Recombinant expression, purification, and characterization of Toxoplasma gondii adenosine kinase. " Molecular and Biochemical Parasitology 1999 September 20; 103(1): pp. 15-23.
  • Hendrickson RC, Douglass JF, Reynolds LD, McNeill PD, Carter D, Reed SG, Houghton RL "Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis." Journal of Clinical Microbiology 2000 June; 38(6): pp. 2354-2361.
  • Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL, Cornellison C, Vedvick TS, Skeiky YAW, and Cheever MA "WT1-specific serum antibodies in patients with leukemia." Clinical Cancer Research 2001 March; 7(3 Suppl): pp. 761s-765s.
  • Douglass J, Jaya NN, Vedvick TS, Reed SG, Zhang Y, Carter D "Chemical Deglycosylation Can Induce Methylation, Succinimide Formation and Isomerization" J Protein Chem. 2001 Oct; 20(7): pp. 571-6.

 

 

 

 

  • Carter D, Douglass JF, Cornellison CD, Retter MW, Johnson JC, Bennington AA, Fleming TP, Reed SG, Houghton RL, Diamond DL, Vedvick TS "Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer" Biochemistry 2002 May 28; 41(21): pp. 6714-22.
  • Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, Cornellison CD, Modabber F, Campos-Neto A, Reed SG. "Immunization with a Polyprotein Vaccine Consisting of the T-Cell Antigens Thiol-Specific Antioxidant, Leishmania major Stress-Inducible Protein 1, and Leishmania Elongation Initiation Factor Protects against Leishmaniasis" Infect Immun 2002 Aug;70(8): pp. 4215-25.
  • Castilleja A, Carter D, Efferson CL, Ward NE, Kawano K, Fisk B, Kudelka AP, Gershenson DM, Murray JL, O'Brian CA, Ioannides CG. "Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex." J Immunol. 2002 Oct 1;169(7): pp. 3545-54.
  • Fanger GR, Houghton RL, Retter MW, Hendrickson RC, Babcook J, Dillon DC, Durham MD, Reynolds LD, Johnson JC, Carter D, Fleming TP, Roche PC, Persing DH, Reed SG. "Detection of mammaglobin in the sera of patients with breast cancer" Tumour Biol 2002 Dec;23(4):pp. 212-21.
  • Carter D, Dillon DC, Reynolds LD, Retter MW, Fanger G, Molesh DA, Sleath P, McNeill PD, Vedvick TS, Reed SG, Persing DH, Houghton RL. "Serum Antibodies to Lipophilin B detected in Late Stage Breast Cancer Patients" 2002 accepted for publication in Clinical Cancer Research.
  • Deborah L. Diamond, Yanni Zhang, Alexander Gaiger, Molly Smithgall, Thomas S. Vedvick, Darrick Carter "Use of Surface Enhanced Laser Desorption Ionization (SELDI) Mass Spectrometry to Identify Differentially Secreted Proteins in Tumor Cell Lines" (manuscript submitted)

Patents

 

  • Wang; T; Bangur; CS; Lodes; MJ; Fanger; GR; Vedvick TS; Carter D; Retter; MW; Mannion J; Fan; L "Compositions and methods for the therapy and diagnosis of lung cancer " United States Patent # 6,504,010 Jan. 3, 2003.

 

Patent Applications

 

  • Wang T, Bangur CS, Lodes MJ, Fanger GR, Vedvick TS, Carter D, Retter MW, and Mannion J. January 4. 2001. "Compositions and methods for the therapy and diagnosis of lung cancer" World Intellectual Property Organization WO0100828 

 

  • Harloker SL, Algate PA, Benson DR, Carter D, Dillon DC, Fling SP, Lodes MJ, Mannion J, Secrist H, Xu J, Mitcham JL; "Compositions and methods for the therapy and diagnosis of ovarian cancer" November 29. 2001 World Intellectual Property Organization WO0190154
  • Carter D, Dillon DC, Houghton RL, Vallieve-Douglass J, Vedvick TS  "Lipophilin complexes for use in cancer diagnosis and therapy" August 16. 2001 AU3691101
  • Maisonneuve JF, Bhatia A, Zhang Y, Carter D, Jen S, Persing DH, Mitcham JL, Skeiky YAW, Wang SS;  "Compositions and methods for the therapy and diagnosis of Acne Vulgaris" November 1. 2001 World Intellectual Property Organization WO0181581
  • Fanger GR, Harlocker SL, Day CH, Jiang Y, Li SX, Retter MW, Carter D, Dillon DC, Kalos MD, Stolk JA, Wang A, Xu J, Henderson RA, Hepler WT, Mitcham JL, Skeiky YAW, Vedvick TS; "Compositions and methods for the therapy and diagnosis of prostate cancer" October 4. 2001 World Intellectual Property Organization WO0173032 
  • Arimilli S, Zhu S, Carter D, Wang A; "Immune mediators and related methods" September 27. 2001 World Intellectual Property Organization WO0170245 
  • Carter D, Dillon DC, Houghton RL, Vallieve-Douglass J, Vedvick TS; "Lipophilin complexes for use in cancer diagnosis and therapy" August 16. 2001 World Intellectual Property Organization WO0158947 
  • Fanger GR, Retter MW, Wang T, Carter D, Lodes MJ, Mannion J, Bangur CS, Vedvick TS "Compositions and methods for the therapy and diagnosis of lung cancer" January 4. 2001 AU5902700